TriSalus Life Sciences Inc.

TLSI | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.98

-$0.12 (-2.35%)

At close: Sep 21, 2026, 4:00 PM ET

$5.07

+$0.09 (+1.81%)

After-hours: Sep 21, 2026, 4:13 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.35%

(1D)

Rating

Updated: Aug 19, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $306.64M

1D Range

4.92 5.20

52W Range

2.20 7.95

Valuation (TTM)

PE -3.83

PB 46.82

EV/EBITDA -13.61

Valuation (NTM)

Forward PE 83.33

Forward PEG 0.20

Price Target $9.50

Cash Flow

FCF Yield -9.8%

SBC Adj. FCF Yield -14.1%

SBC Impact -44.1%

Margins

Gross Margin 85.8%

Operating Margin -67.7%

FCF Margin -66.3%

Growth (CAGR)

Revenue 3Y | 5Y 45.1% | 37.3%

Dil EPS 3Y | 5Y 28.8% | -14.4%

FCF 3Y | 5Y 33.8% | 0.9%

Returns

ROA -45.2%

ROE 273.7%

ROIC -59.2%

Financial Health

Net Cash

$11.86M

Current Ratio 5.35

Interest Coverage -5.23

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver an...

Sector Healthcare

Industry Medical - Devices

Employees 102

IPO Date Feb 7, 2021

Website trisaluslifesci.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$9.50

Upside

+90.76%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞